Evidence map›Paper›PMID 35342923›Full record

Trial reportPediatrics2022

Safety of Live Attenuated Influenza Vaccine in Children With Asthma.

Andrew G Sokolow, Amy P Stallings, Carolyn Kercsmar, Theresa Harrington, Natalia Jimenez-Truque, Yuwei Zhu, Katherine Sokolow, M Anthony Moody, Elizabeth P Schlaudecker, Emmanuel B Walter and 3 more

Erratum issuedOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The role of innate immune system in respiratory viral infection related asthma.Frontiers in cellular and infection microbiology · 2025
    Review
  4. Article
  5. Article
  6. Monitoring Vaccine Safety: United States Vaccine Safety Surveillance Systems.Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Andrew G Sokolow *Division of Allergy, Immunology, and Pulmonary Medicine.
Amy P Stallings *Division of Allergy and Immunology.
Carolyn KercsmarDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Theresa HarringtonImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Natalia Jimenez-TruqueVanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee.
Yuwei ZhuBiostatistics.
Katherine SokolowDepartments ofPediatrics.
M Anthony MoodyDepartment of Pediatrics.
Elizabeth P SchlaudeckerDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Emmanuel B WalterDepartment of Pediatrics.
Mary Allen StaatDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Karen R BroderImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
C Buddy CreechVanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee.
Cincinnati Children's Hospital Medical Center · USVanderbilt University Medical Center · USDuke University · USCancer Research And Biostatistics · USCenters for Disease Control and Prevention · USNational Center for Immunization and Respiratory Diseases · USNational Institute of Allergy and Infectious Diseases · USPulmonary and Allergy Associates · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAsthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged ≥5 years because of concerns for wheezing events. We evaluated the safety of LAIV4 in children with asthma, comparing the proportion of children with asthma exacerbations after LAIV4 or quadrivalent inactivated influenza vaccine (IIV4).

methodsWe enrolled 151 children with asthma, aged 5 to 17 years, during 2 influenza seasons. Participants were randomly assigned 1:1 to receive IIV4 or LAIV4 and monitored for asthma symptoms, exacerbations, changes in peak expiratory flow rate (PEFR), and changes in the asthma control test for 42 days after vaccination.

resultsWe included 142 participants in the per-protocol analysis. Within 42 days postvaccination, 18 of 142 (13%) experienced an asthma exacerbation: 8 of 74 (11%) in the LAIV4 group versus 10 of 68 (15%) in the IIV4 group (LAIV4-IIV4 = -0.0390 [90% confidence interval -0.1453 to 0.0674]), meeting the bounds for noninferiority. When adjusted for asthma severity, LAIV4 remained noninferior to IIV4. There were no significant differences in the frequency of asthma symptoms, change in PEFR, or childhood asthma control test/asthma control test scores in the 14 days postvaccination between LAIV4 and IIV4 recipients. Vaccine reactogenicity was similar between groups, although sore throat (P = .051) and myalgia (P <.001) were more common in the IIV4 group.

conclusionsLAIV4 was not associated with increased frequency of asthma exacerbations, an increase in asthma-related symptoms, or a decrease in PEFR compared with IIV4 among children aged 5 to 17 years with asthma.

Indexed as

AsthmaInfluenza, HumanInfluenza VaccinesAdolescentChildChild, PreschoolHumansVaccines, AttenuatedVaccines, InactivatedInfluenza VaccinesVaccines, AttenuatedVaccines, Inactivated

Identifiers

PMID35342923
PMCPMC11235090
OpenAlexW4220899352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.